Security key
30049G203
- Type / Class
- Equity / Common Shares
- Shares outstanding
- 1,582,162
- Total 13F shares
- 59,166
- Share change
- -9,748
- Total reported value
- $97,415
- Price per share
- $1.65
- Number of holders
- 9
- Value change
- -$18,661
- Number of buys
- 2
- Number of sells
- 3
Report period
Q2 2023
Institutions
9
Top holders
9
EVOK full security history
Newer quarter: Q3 2023
Previous quarter: Q1 2023
Evoke Pharma Inc SEC filings
Evoke Pharma Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 30049G203
Recent filing periods:
Top shareholders of EVOK - Evoke Pharma, Inc. - Common Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
1.9%
|
29,851
|
$56,717 | — | 31 Mar 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
20,894
|
$39,698 | — | 31 Mar 2023 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.71%
|
11,178
|
$21,000 | — | 31 Mar 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.25%
|
3,985
|
$8,000 | — | 31 Mar 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.09%
|
1,473
|
$2,799 | — | 31 Mar 2023 | |
| UBS Group AG |
13F
|
Company |
0.07%
|
1,107
|
$2,103 | — | 31 Mar 2023 | |
| NewEdge Advisors, LLC |
13F
|
Company |
0.01%
|
208
|
$395 | — | 31 Mar 2023 | |
| Concord Wealth Partners |
13F
|
Company |
0.01%
|
114
|
$217 | — | 31 Mar 2023 | |
| Lindbrook Capital, LLC |
13F
|
Company |
0.01%
|
83
|
$158 | — | 31 Mar 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
16
|
$30 | — | 31 Mar 2023 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
5
|
$10 | — | 31 Mar 2023 | |
| Ann D. Rhoads |
3/4/5
|
Director |
—
class O/S missing
|
61,750
|
— | — | 05 May 2021 | |
| David A. Gonyer |
3/4/5
|
CEO, Director |
—
class O/S missing
|
30,000
|
— | — | 08 Feb 2023 |
Institutional Holders of Evoke Pharma, Inc. - Common Shares (EVOK) as of Q2 2023
As of 30 Jun 2023,
Evoke Pharma, Inc. - Common Shares (EVOK) was held by
9 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
59,166 shares.
The largest 9 holders included
VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Tower Research Capital LLC (TRC), BlackRock Inc., UBS Group AG, NewEdge Advisors, LLC, Concord Wealth Partners, WELLS FARGO & COMPANY/MN, and Federation des caisses Desjardins du Quebec.
This page lists
9
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2023 vs Q1 2023 Across Filers
Q1 2023 holders
11
Q2 2023 holders
9
Holder diff
-2
| Investor | Q1 2023 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q1 2023 Value $ | Q2 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.